In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.

We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.

Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.

Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.

CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

Most biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.

For Castle Creek Biosciences, there are many stakes at play in targeting rare skin, connective tissue, liver, and metabolic disorders.

In part 2 of this series, we cover each company’s future plans, as well as their leaders’ observations of the platform-to-pipeline space they are effectively expanding, by joining a gathering crowd of companies now entering it.

What if, for certain ambitious but traditionally underfunded areas needing innovation, a startup could achieve its ends without the usual for-profit incentives?

Global Blood Therapeutics is intertwining science, business, and social missions to make progress against sickle cell disease.

To discover why companies go about transforming themselves from technology suppliers into biotherapeutics developers, we spoke with the heads of five companies built upon novel platforms for discovery or development of new biotherapeutics, though at various stages and differences in applied strategies.